Posttransplant hyperlipidemia increases cardiovascular morbidity and mortality rate in renal transplant recipients. It also leads to graft loss due to atherosclerosis and glomerular damage. It is essential to control hyperlipidemia in renal transplant recipients to prevent these events.
Methods
In our study, we determined lipid profiles in 59 renal transplant recipients. Twenty of the recipients had hyperlipidemia; 9 had type IV, and 11 had type II hyperlipoproteinemia. Randomly selected 14 of 20 hyperlipidemic patients consisted of the diet group and were treated with American phase 3 diet for 1 month. Randomly selected 6 of the 20 hyperlipidemic patients received their regular diet as the control group. Five diet-resistant patients in the American phase 3 diet group were given diet plus placebo for another 1 month and then they were given diet plus Gemfibrozil (600 mg twice a day) for 2 months.
Results
Lipid profile was normalized in 9 of the 14 patients on American phase 3 diet. The lipid profile of 5 patients in the American phase 3 diet group did not change significantly after 1-month diet. These 5 diet-resistant patients were given diet plus placebo for another 1 month, and their lipid levels again did not change significantly. Afterward, they were treated with Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months. At the end of this therapy period, their cholesterol level and triglyceride level decreased significantly. No change was observed in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels.
Conclusions
We conclude that American phase 3 diet and/or Gemfibrozil are effective in controlling posttransplant hyperlipidemia in renal transplant recipients.
BuchananC, SmithL, CorbettJ, . A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant. 2006;6(4):770–774.
2.
KimakE, KsiazekA, Baranowicz-GaszczykI, . Disturbed lipids, lipoproteins and triglyceride-rich lipoproteins as well as fasting and nonfasting non-high-density lipoprotein cholesterol in post-renal transplant patients. Ren Fail. 2007;29(6):705–712.
3.
DograG, IrishA, ChanD, . A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis. 2007;49(6):776–785.
4.
KobashigawaJA, KasiskeBL.Hyperlipidemia in solid organ transplantation. Transplantation. 1997;63(3):331–338.
5.
PadiyarA, AkoumFH, HricikDE.Management of the kidney transplant recipient. Prim Care. 2008;35(3):433–450, v.
6.
ShiraliAC, BiaMJ.Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol. 2008;3(2):491–504.
7.
LisikW, SchoenbergL, LaskyRE, . Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen. Transplant Proc. 2007;39(10):3086–3092.
8.
PorriniE, DelgadoP, AlvarezA, . The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant. 2008;23(4):1436–1441.
9.
PerreaDN, MoulakakisKG, PoulakouMV, . Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol. 2008;40(2):521–527.
10.
RamezaniM, EinollahiB, Ahmadzad-AslM, . Hyperlipidemia after renal transplantation and its relation to graft and patient survival. Transplant Proc. 2007;39(4):1044–1047.
11.
SoveriI, HoldaasH, JardineA, . Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant. 2006;21(8):2282–2289.
12.
DursunB, DursunECaprazI, . Are uremia, diabetes, and atherosclerosis linked with impaired antioxidant mechanisms?J Investig Med. 2008;56(2):545–552.
13.
DursunB, DursunE, SuleymanlarG, . Carotid artery intima-media thickness correlates with oxidative stress in chronic haemodialysis patients with accelerated atherosclerosis. Nephrol Dial Transplant. 2008;23(5):1697–1703.
14.
DursunBDursunESuleymanlarG, . The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress. J Diabetes Complications. 2008. Feb22 [Epub ahead of print].
15.
DursunEDursunBSuleymanlarG, . Carbonyl stress in chronic renal failure: the effect of haemodialysis. Ann Clin Biochem. 2005;42(Pt 1):64–66.
16.
DursunEDursunBSuleymanlarG, . Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus. Acta Diabetol. 2005;42(3):123–128.
17.
DursunE, TimurM, DursunB, . Protein oxidation in Type 2 diabetic patients on hemodialysis. J Diabetes Complications. 2005;19(3):142–146.
18.
DursunE, OzbenT, SuleymanlarG, . Effect of hemodialysis on the oxidative stress and antioxidants. Clin Chem Lab Med. 2002;40(10):1009–1013.
19.
ColeTG, BowenPE, SchmeisserD, . Differential reduction of plasma cholesterol by the American Heart Association Phase 3 Diet in moderately hypercholesterolemic, premenopausal women with different body mass indexes. Am J Clin Nutr. 1992;55(2):385–394.
20.
FinleyPR, SchifmanRB, WilliamsRJ, . Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement. Clin Chem. 1978;24(6):931–933.
21.
FriedewaldWT, LevyRI, FredricksonDS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
22.
BackesJM, GibsonCA, RuisingerJF, . Fibrates: what have we learned in the past 40 years?Pharmacotherapy. 2007;27(3):412–424.
23.
BaigentC, KeechA, KearneyPM, . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
24.
PedersenTR, FaergemanO, KasteleinJJ, . High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA.2005;294(19):2437–2445.
25.
WierzbickiAS, MikhailidisDP, WrayR, . Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin. 2003;19(3):155–168.
26.
KohnleMPietruckFKribbenA, . Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant. 2006;6(1):205–208.
27.
MuchaKForoncewiczBOldakowskaJU, . How to choose a statin after kidney transplantation: case analyses. Transplant Proc. 2006;38(1):161–164.
28.
KeechA, SimesRJ, BarterP, . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
29.
ScottR, BestJ, ForderP, . Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].Cardiovasc Diabetol. 2005;4:13.
30.
EricssonCG, HamstenA, NilssonJ, . Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347(9005):849–853.
31.
FrickMH, SyvanneM, NieminenMS, . Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997;96(7):2137–2143.
32.
Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet.2001;357(9260):905–910.
33.
Israeli Society for Prevention of Heart Attacks. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000;102(1):21–27.
34.
RubinsHB, RobinsSJ, CollinsD, . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–418.
35.
TenenbaumA, MotroM, FismanEZ, . Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165(10):1154–1160.
36.
SpinelliGA, FelipeCR, MachadoPG, . Relationship of cyclosporin and sirolimus blood concentrations regarding the incidence and severity of hyperlipidemia after kidney transplantation. Braz J Med Biol Res. 2006;39(1):19–30.
37.
KirkJK, DupuisRE.Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother. 1995;29(9):879–891.
38.
ChanMK, VargheseZ, PersaudJW, . The role of multiple pharmaco-therapy in the pathogenesis of hyperlipidemia after renal transplantation. Clin Nephrol. 1981;15(6):309–313.
39.
ApanayDC, NeylanJF, RagabMS, . Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation. 1994;58(6):663–669.
40.
SuleymanlarG, OzbenT, SapanM, . Serum lipoproteins in renal transplant patients: the effect of cyclosporine on lipoprotein(a). Transplant Proc. 1994;26(5):2637–2638.
41.
MorrisettJD, Abdel-FattahG, HoogeveenR, . Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43(8):1170–1180.
42.
KahanBD, KramerWG.Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharmacol Ther. 2001;70(1):74–81.
